StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$3.15+0.15 (+5.00%)

Close on Nov 18, 2026Market cap $12.44MP/E –Yield –

Onconetix revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Onconetix's revenue for the twelve months ending Jun 30, 2026 was $645.82K, down 51.3% year over year. For fiscal 2025 it was $815.37K, down 67.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$815.37K-67.7%
FY2024Dec 31, 2024$2.52M+4217.3%
FY2023Dec 31, 2023$58.47K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.12K-83.9%
Q1 FY2026Mar 31, 2026$21.46K-78.9%
Q4 FY2025Dec 31, 2025$303.60K-57.4%
Q3 FY2025Sep 30, 2025$303.65K-25.4%
Q2 FY2025Jun 30, 2025$106.49K-84.9%
Q1 FY2025Mar 31, 2025$101.63K-85.5%
Q4 FY2024Dec 31, 2024$711.98K–
Q3 FY2024Sep 30, 2024$406.86K–
Q2 FY2024Jun 30, 2024$704.85K–
Q1 FY2024Mar 31, 2024$700.43K–

More Onconetix figures

See a number that looks wrong?